TAUNS Laboratories, Inc. Logo

TAUNS Laboratories, Inc.

Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.

197A | T

Overview

Corporate Details

ISIN(s):
JP3452250008
LEI:
Country:
Japan
Address:
伊豆の国市神島761番1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TAUNS Laboratories, Inc., founded in 1987, is a company engaged in the development, manufacture, and sale of in vitro diagnostics (IVD) and research reagents. The company's mission is to enrich lives and provide peace of mind through its proprietary diagnostic technologies. Its main products include antigen test kits for infectious diseases and various analytical reagents. A key focus for the company is the development of patient-friendly products for global consumption, facilitated through its export and import operations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 09:49
Registration Form
確認書
Japanese 8.1 KB
2025-09-25 09:47
Annual Report
有価証券報告書-第10期(2024/07/01-2025/06/30)
Japanese 2.0 MB
2025-02-13 07:30
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-02-13 07:30
Interim Report
半期報告書-第10期(2024/07/01-2025/06/30)
Japanese 174.5 KB
2024-09-30 03:19
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2024-09-27 08:00
Registration Form
確認書
Japanese 8.1 KB
2024-09-27 08:00
Governance Information
内部統制報告書-第9期(2023/07/01-2024/06/30)
Japanese 22.1 KB
2024-09-27 08:00
Annual Report
有価証券報告書-第9期(2023/07/01-2024/06/30)
Japanese 1.9 MB
2024-06-12 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-06-04 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-05-17 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.7 MB

Automate Your Workflow. Get a real-time feed of all TAUNS Laboratories, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAUNS Laboratories, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAUNS Laboratories, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX
Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT
Pulmatrix, Inc. Logo
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America
PULM
PUMA BIOTECHNOLOGY, INC. Logo
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America
PBYI
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland
PUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.